Tissue Regenix Group plc, is a United Kingdom-based holding company. It is a regenerative medical devices company, which uses animal or human tissue to replace damaged or worn out parts of the human body. The Principal activity of the Company is exploitation of platform technologies in the field of tissues engineering and regenerative medicine. It focuses on developing a number of products, addressing a range of needs across multiple therapeutic areas, utilising its platform technology, dCell. The dCell process is used to create biological scaffolds by decellularising human or animal tissue. As of January 31, 2012, the dCell process has been used with human donor valves in over 140 patients. In November 2012, it has set up a subsidiary company in the United States, as part of its commercialization strategy for its dCELL technology platform.